Assuntos
COVID-19 , Hipersensibilidade , COVID-19/epidemiologia , COVID-19/prevenção & controle , Vacinas contra COVID-19/efeitos adversos , Europa (Continente)/epidemiologia , Humanos , Hipersensibilidade/diagnóstico , Hipersensibilidade/epidemiologia , Hipersensibilidade/etiologia , SARS-CoV-2 , Estados Unidos/epidemiologiaRESUMO
The availability of effective smallpox vaccines was a critical element of the successful eradication of smallpox in 1980. Antibody responses play a primary role in protective immunity and neutralizing antibody is an established correlate of protection against smallpox. In this study we used a poxvirus proteome array to assess the antibody response to individual viral proteins in a cohort of 1,037 smallpox vaccine recipients. Several statistically significant differences were observed in the antibody response to immunodominant proteins between men and women, including B5R-a major target of neutralizing antibody in vaccinia immune globulin, and the membrane proteins D8L and A27L, both of which have been used as vaccine antigens providing protection in animal models. We also noted differences across racial/ethnic groups. In this cohort, which consisted of both ACAM2000 and Dryvax recipients, we noted minute differences in the antibody responses to a restricted number of viral proteins, providing additional support for the use of ACAM2000 as a replacement smallpox vaccine. Furthermore, our data indicate that poxvirus proteome microarrays can be valuable for screening and monitoring smallpox vaccine-induced humoral immune responses in large-scale serologic surveillance studies and prove useful in the guidance of developing novel smallpox candidate vaccines.
Assuntos
Vacina Antivariólica , Varíola , Animais , Anticorpos Antivirais , Feminino , Humanos , Imunidade Humoral , Masculino , Testes de Neutralização , Proteômica , Varíola/prevenção & controle , Vaccinia virusRESUMO
Given the social and economic upheavals caused by the COVID-19 pandemic, political leaders, health officials, and members of the public are eager for solutions. One of the most promising, if they can be successfully developed, is vaccines. While the technological development of such countermeasures is currently underway, a key social gap remains. Past experience in routine and crisis contexts demonstrates that uptake of vaccines is more complicated than simply making the technology available. Vaccine uptake, and especially the widespread acceptance of vaccines, is a social endeavor that requires consideration of human factors. To provide a starting place for this critical component of a future COVID-19 vaccination campaign in the United States, the 23-person Working Group on Readying Populations for COVID-19 Vaccines was formed. One outcome of this group is a synthesis of the major challenges and opportunities associated with a future COVID-19 vaccination campaign and empirically-informed recommendations to advance public understanding of, access to, and acceptance of vaccines that protect against SARS-CoV-2. While not inclusive of all possible steps than could or should be done to facilitate COVID-19 vaccination, the working group believes that the recommendations provided are essential for a successful vaccination program.
Assuntos
COVID-19 , Vacinas , Vacinas contra COVID-19 , Humanos , Pandemias/prevenção & controle , SARS-CoV-2 , Estados Unidos , VacinaçãoAssuntos
Vacinas contra COVID-19/administração & dosagem , Vacinas contra COVID-19/provisão & distribuição , COVID-19/prevenção & controle , Alocação de Recursos para a Atenção à Saúde/ética , COVID-19/epidemiologia , COVID-19/transmissão , Tomada de Decisão Clínica , Atenção à Saúde/ética , Geriatria/ética , Política de Saúde , Humanos , Programas de Imunização/ética , Programas de Imunização/métodos , Pandemias , Fatores de Risco , SARS-CoV-2/imunologia , SARS-CoV-2/isolamento & purificação , Vacinação/ética , Vacinação/métodos , Eliminação de Partículas ViraisAssuntos
Infecções por Coronavirus/prevenção & controle , Infecções por Coronavirus/virologia , Vacinas Virais , Animais , COVID-19 , China/epidemiologia , Doenças Transmissíveis Emergentes/epidemiologia , Infecções por Coronavirus/epidemiologia , Infecções por Coronavirus/etiologia , Infecções por Coronavirus/transmissão , Surtos de Doenças , Desenvolvimento de Medicamentos/economia , Humanos , Pandemias/prevenção & controle , Pneumonia Viral/etiologia , Pneumonia Viral/prevenção & controle , Saúde Pública , Síndrome Respiratória Aguda Grave/epidemiologia , Vacinas Virais/imunologia , Vacinas Virais/farmacologia , Organização Mundial da SaúdeRESUMO
We investigated and compared current national vaccination policies for health-care personnel (HCP) in Europe with results from our previous survey. Data from 36 European countries were collected using the same methodology as in 2011. National policies for HCP immunization were in place in all countries. There were significant differences in terms of number of vaccinations, target HCP and healthcare settings, and implementation regulations (recommended or mandatory vaccinations). Vaccination policies against hepatitis B and seasonal influenza were present in 35 countries each. Policies for vaccination of HCP against measles, mumps, rubella and varicella existed in 28, 24, 25 and 19 countries, respectively; and against tetanus, diphtheria, pertussis and poliomyelitis in 21, 20, 19, and 18 countries, respectively. Recommendations for hepatitis A immunization existed in 17 countries, and against meningococcus B, meningococcus C, meningococcus A, C, W, Y, and tuberculosis in 10, 8, 17, and 7 countries, respectively. Mandatory vaccination policies were found in 13 countries and were a pre-requisite for employment in ten. Comparing the vaccination programs of the 30 European countries that participated in the 2011 survey, we found that more countries had national vaccination policies against measles, mumps, rubella, hepatitis A, diphtheria, tetanus, poliomyelitis, pertussis, meningococcus C and/or meningococcus A, C, W, Y; and more of these implemented mandatory vaccination policies for HCP. In conclusion, European countries now have more comprehensive national vaccination programs for HCP, however there are still gaps. Given the recent large outbreaks of vaccine-preventable diseases in Europe and the occupational risk for HCP, vaccination policies need to be expanded and strengthened in several European countries. Overall, vaccination policies for HCP in Europe should be periodically re-evaluated in order to provide optimal protection against vaccine-preventable diseases and infection control within healthcare facilities for HCP and patients.
Assuntos
Pessoal de Saúde , Política de Saúde , Programas de Imunização/legislação & jurisprudência , Vacinação/legislação & jurisprudência , Europa (Continente) , Humanos , Programas Obrigatórios/legislação & jurisprudência , Saúde OcupacionalRESUMO
Older adults are disproportionately affected by influenza morbidity and mortality. In most high income countries, influenza vaccine policies target persons age ≥65â¯years for influenza vaccination. Many low-resource settings do not utilize seasonal influenza vaccination. Barriers to influenza prevention among older adults around the globe are multiple and some vary between high- and low-resource settings. To maximize influenza prevention in the older adult population, gaps in influenza vaccination coverage and improvements in vaccine efficacy are needed. The focus of this article is on the data for currently available vaccine strategies to maximize influenza vaccine impact, with a focus on high-resource settings. We also discuss novel influenza vaccine strategies needed for older adults worldwide.
Assuntos
Saúde Global , Vacinas contra Influenza/uso terapêutico , Influenza Humana/prevenção & controle , Cobertura Vacinal/estatística & dados numéricos , Adjuvantes Imunológicos/administração & dosagem , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Recursos em Saúde , Humanos , Hospedeiro Imunocomprometido , Influenza Humana/epidemiologia , Estações do Ano , Vacinação/economia , Vacinação/legislação & jurisprudênciaAssuntos
Erradicação de Doenças , Vacinação em Massa , Meningite Meningocócica/epidemiologia , Meningite Meningocócica/prevenção & controle , Poliomielite/epidemiologia , Poliomielite/prevenção & controle , África Subsaariana/epidemiologia , Criança , Erradicação de Doenças/estatística & dados numéricos , Erradicação de Doenças/tendências , Indústria Farmacêutica , Humanos , Cooperação Internacional , Vacinação em Massa/economia , Vacinas Meningocócicas/economia , Vacinas Meningocócicas/provisão & distribuição , Poliomielite/economia , Poliomielite/virologia , Poliovirus/isolamento & purificação , Vacinas contra Poliovirus , Vigilância em Saúde Pública , Adulto JovemRESUMO
Health care reform calls for the nursing profession, with a focus on disease prevention and health restoration, to innovate and create new models of care that are client-centric, evidence-based, and cost-effective. To do so, nurses must develop a fundamentally different paradigm and epistemology. New care models are required that focus on issues such as evidence-based prevention. Among the prevention foci for hospitals are hospital-acquired infections, including influenza, which kills 36,000 Americans annually. One crucial step in eliminating hospital-acquired influenza is to require influenza vaccination of all health care workers. This article challenges nursing leadership to seize opportunities to lead health care initiatives and encourage courageous innovative actions that depart from old paradigms; these actions must be based on scientific evidence, reduce costs, and promote patient safety and quality care and outcomes.
Assuntos
Enfermagem Baseada em Evidências/métodos , Reforma dos Serviços de Saúde , Controle de Infecções/métodos , Transmissão de Doença Infecciosa do Profissional para o Paciente/prevenção & controle , Influenza Humana/prevenção & controle , Enfermagem/organização & administração , Assistência Centrada no Paciente/métodos , Análise Custo-Benefício , Humanos , Liderança , Segurança do Paciente , Qualidade da Assistência à Saúde , Estados Unidos , VacinaçãoRESUMO
OBJECTIVE: To increase influenza vaccination rates among industrial employees and their families through a campaign at a large corporation. METHODS: This prospective, multisite study used employee surveys and claims data to evaluate an evidence-based worksite vaccination program. RESULTS: Vaccination rates among insured employees and dependents (N = 13,520) increased significantly after the intervention (P < 0.001). More than 90% of vaccinated employees received vaccine at employer-sponsored events. There was a strong association between employee and family vaccination status. Primary reasons for receiving the vaccine were economic (free 84%; convenient 80%; avoid absenteeism 82%), rather than health-related. Knowledge was associated with vaccination, but customized education did not change beliefs. CONCLUSIONS: Worksite programs can demonstrably increase vaccination rates among industrial employees and families. Consideration should be given to repositioning vaccination from medical treatment to community initiatives offered with other worksite health promotion programs.
Assuntos
Participação da Comunidade/estatística & dados numéricos , Influenza Humana/prevenção & controle , Saúde Ocupacional , Vacinação/estatística & dados numéricos , Adulto , Participação da Comunidade/psicologia , Tomada de Decisões , Família , Feminino , Conhecimentos, Atitudes e Prática em Saúde , Humanos , Indústrias , Seguro Saúde , Masculino , Pessoa de Meia-Idade , Vacinação/psicologia , Local de TrabalhoAssuntos
Vacinas contra Influenza/administração & dosagem , Vacinas contra Influenza/imunologia , Influenza Humana/epidemiologia , Influenza Humana/prevenção & controle , Tecnologia Farmacêutica/métodos , Idoso , Criança , Pré-Escolar , Política de Saúde , Humanos , Lactente , Vacinas contra Influenza/economia , Influenza Humana/mortalidade , Tecnologia Farmacêutica/economiaRESUMO
The aim of this study was to evaluate existing policies regarding recommended and mandatory occupational vaccinations for health-care workers (HCWs) in Europe. A standardized questionnaire was sent to experts in Infection Control or Occupational Health in all 27 European Union Member States, as well as Norway, Russia, and Switzerland. All 30 countries have established policies about HCW vaccination against vaccine-preventable diseases. However significant gaps and considerable country-to-country variation were found, in terms of number of recommended vaccines and target subgroups of HCWs and health-care settings. Vaccination against hepatitis B and annual vaccination against seasonal influenza are almost universally recommended for HCWs in Europe (29 countries each, including eight countries where vaccination against hepatitis B is mandatory or required for employment). Policies regarding HCW vaccination also exist against mumps (12 countries), measles or rubella (15 countries), varicella (17 countries), diphtheria-tetanus (14 countries), pertussis (9 countries), poliomyelitis (11 countries), hepatitis A (11 countries), tuberculosis (BCG vaccine) (9 countries), and against meningococcus group C or meningococci groups A, C, W135, Y (tetravalent vaccine) (in 4 countries each). Re-evaluation of occupational vaccine policies for HCWs in Europe on a consensus basis is imperative in order to promote HCW and patient safety.
Assuntos
Pessoal de Saúde , Política de Saúde , Vacinação , Europa (Continente) , Instalações de Saúde , Humanos , Programas de Imunização , Controle de Infecções , Programas Obrigatórios , Inquéritos e QuestionáriosRESUMO
BACKGROUND: The mechanisms of immune response are structured within a highly complex regulatory system. Genetic associations with variation in the immune response to rubella vaccine have typically been assessed one locus at a time. We simultaneously assessed the associations between 726 SNPs tagging 84 candidate immune response genes and rubella-specific antibody levels. Blood samples were obtained from 714 school-aged children who had received two doses of MMR vaccine. Associations between rubella-specific antibody levels and 726 candidate tagSNPs were assessed both one SNP at a time and in a variety of multigenic analyses. RESULTS: Single-SNP assessments identified 4 SNPs that appeared to be univariately associated with rubella antibody levels: rs2844482 (p = 0.0002) and rs2857708 (p = 0.001) in the 5'UTR of the LTA gene, rs7801617 in the 5'UTR of the IL6 gene (p = 0.0005), and rs4787947 in the 5'UTR of the IL4R gene (p = 0.002). While there was not significant evidence in favor of epistatic genetic associations among the candidate SNPs, multigenic analyses identified 29 SNPs significantly associated with rubella antibody levels when selected as a group (p = 0.017). This collection of SNPs included not only those that were significant univariately, but others that would not have been identified if only considered in isolation from the other SNPs. CONCLUSIONS: For the first time, multigenic assessment of associations between candidate SNPs and rubella antibody levels identified a broad number of genetic associations that would not have been deemed important univariately. It is important to consider approaches like those applied here in order to better understand the full genetic complexity of response to vaccination.
Assuntos
Anticorpos Antivirais/biossíntese , Interleucina-6/genética , Lectinas/genética , Vacina contra Sarampo-Caxumba-Rubéola , Receptores de Interleucina-4/genética , Rubéola (Sarampo Alemão)/prevenção & controle , Adolescente , Anticorpos Antivirais/sangue , Anticorpos Antivirais/genética , Criança , Estudos de Associação Genética , Humanos , Polimorfismo de Nucleotídeo Único , População , Rubéola (Sarampo Alemão)/epidemiologia , Rubéola (Sarampo Alemão)/genética , Rubéola (Sarampo Alemão)/imunologia , VacinaçãoRESUMO
Influenza is an important contributor to population and individual morbidity and mortality. The current influenza pandemic with novel H1N1 has highlighted the need for health care professionals to better understand the processes involved in creating influenza vaccines, both for pandemic as well as for seasonal influenza. This review presents an overview of influenza-related topics to help meet this need and includes a discussion of the burden of disease, virology, epidemiology, viral surveillance, and vaccine strain selection. We then present an overview of influenza vaccine-related topics, including vaccine production, vaccine efficacy and effectiveness, influenza vaccine misperceptions, and populations that are recommended to receive vaccination. English-language articles in PubMed published between January 1, 1970, and October 7, 2009, were searched using key words human influenza, influenza vaccines, influenza A, and influenza B.
Assuntos
Surtos de Doenças/prevenção & controle , Indústria Farmacêutica/métodos , Vacinas contra Influenza/provisão & distribuição , Influenza Humana/prevenção & controle , Humanos , Vírus da Influenza A Subtipo H1N1/imunologia , Vírus da Influenza B/imunologia , Influenza Humana/epidemiologia , Estados Unidos/epidemiologiaRESUMO
Little is known about the influence of asthma status on humoral and cell-mediated immune responses to measles-mumps-rubella (MMR) vaccine viruses. We compared the virus-specific IgG levels and lymphoproliferative response of peripheral blood mononuclear cells to MMR vaccine viruses between asthmatic and nonasthmatic patients. The study subjects included 342 healthy children aged 12-18 years who had received two doses of the MMR vaccine. We ascertained asthma status by applying predetermined criteria. Of the 342 subjects, 230 were available for this study of whom 25 were definite asthmatic patients (10.9%) and the rest of subjects were nonasthmatic patients. The mean of the log-transformed lymphoproliferative responses between definite asthma and nonasthma who had a family history of asthma were for measles, 0.92 ± 0.31 versus 1.54 ± 0.17 (p = 0.125); for mumps, 0.98 ± 0.64 versus 2.20 ± 0.21 (p = 0.035); and for rubella, 0.12 ± 0.37 versus 0.97 ± 0.16 (p = 0.008), respectively, adjusting for the duration between the first MMR vaccination and determination of the immune responses. There were no such differences among children without a family history of asthma. MMR virus-specific IgG levels were not different between study subjects with or without asthma. The study findings suggest asthmatic patients may have a suboptimal cell-mediated immune response to MMR vaccine viruses and a family history of asthma modifies this effect.
Assuntos
Asma/imunologia , Vacina contra Sarampo-Caxumba-Rubéola/administração & dosagem , Linfócitos T/metabolismo , Viroses/imunologia , Adolescente , Antígenos Virais/imunologia , Asma/complicações , Asma/terapia , Proliferação de Células , Criança , Suscetibilidade a Doenças/imunologia , Feminino , Humanos , Imunidade Celular , Imunidade Humoral , Imunoglobulina G/sangue , Masculino , Linfócitos T/imunologia , Linfócitos T/patologia , Viroses/complicações , Viroses/prevenção & controleRESUMO
Besides natural disasters and naturally occurring novel infectious diseases, nothing potentially threatens the health and stability of nations and health systems as much as the devastating threat and unfathomability of bioterrorism. Other than attempts at political solutions and interdictive attempts, only antimicrobials and vaccines offer possible means for protection. Of these, vaccines offer the most immediate and definitive of preventive solutions. Limiting the development and use of vaccines however are social, political, ethical, and economic considerations, and this article will provide a brief exploration of each of these issues and the intersection with the need for such vaccines. In this article we define bioterrorism as the deliberate use of naturally occurring or bioengineered microorganisms in order to cause harm to people, animals, or plants.